# hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients

> **NCT00285194** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 6 (—)

## Conditions studied

- Type 1 Diabetes
- Hypoglycemia

## Interventions

- **DRUG:** Allogeneic Islets of Langerhans
- **DRUG:** hOKT3γ1 (Ala-Ala)

## Key facts

- **NCT ID:** NCT00285194
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 6 (—)
- **Last updated:** 2012-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00285194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00285194, "hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00285194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*